{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:17:41Z","timestamp":1780600661562,"version":"3.54.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Stiftung Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.hoc.2025.12.001","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:09:54Z","timestamp":1768306194000},"page":"165-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Circulating Tumor DNA Assessment in Classic Hodgkin Lymphoma: Ready for Primetime?"],"prefix":"10.1016","volume":"40","author":[{"given":"Tanja","family":"Zamrik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Alig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10310","key":"10.1016\/j.hoc.2025.12.001_bib1","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.001_bib2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.001_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/asheducation-2016.1.323","article-title":"Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment","volume":"2016","author":"van Leeuwen","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.001_bib4","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the childhood cancer survivor study","volume":"117","author":"Castellino","year":"2011","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2025.12.001_bib5","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.hoc.2025.12.001_bib6","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.001_bib7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"Calgb 50604: risk-adapted treatment of nonbulky early-stage hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.hoc.2025.12.001_bib8","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.001_bib9","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(21)00101-0","article-title":"PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Kreissl","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2025.12.001_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720914490","article-title":"PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma","volume":"11","author":"Lang","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.001_bib11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1200\/JCO.21.01777","article-title":"Positron emission tomography-driven strategy in advanced hodgkin lymphoma: prolonged Follow-Up of the AHL2011 phase III lymphoma study association study","volume":"40","author":"Casasnovas","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10450","key":"10.1016\/j.hoc.2025.12.001_bib12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.001_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2025.12.001_bib14","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.001_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4329\/wjr.v9.i2.27","article-title":"Evaluation of response to immune checkpoint inhibitors: is there a role for positron emission tomography?","volume":"9","author":"Bauckneht","year":"2017","journal-title":"World J Radiol"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.001_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11030217","article-title":"Early evaluation of immunotherapy response in lymphoma patients by 18F-FDG PET\/CT: a literature overview","volume":"11","author":"Ferrari","year":"2021","journal-title":"J Pers Med"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.001_bib17","doi-asserted-by":"crossref","first-page":"6536","DOI":"10.1007\/s00330-022-08669-8","article-title":"Interpretation of 2-[(18)F]FDG PET\/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors","volume":"32","author":"Manson","year":"2022","journal-title":"Eur Radiol"},{"issue":"9828","key":"10.1016\/j.hoc.2025.12.001_bib18","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"issue":"10114","key":"10.1016\/j.hoc.2025.12.001_bib19","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.001_bib20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.001_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.hoc.2025.12.001_bib22","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2025.12.001_bib23","article-title":"Flow-sorting and exome sequencing of the reed-sternberg cells of classical hodgkin lymphoma","volume":"124","author":"Reichel","year":"2017","journal-title":"J Vis Exp"},{"issue":"22","key":"10.1016\/j.hoc.2025.12.001_bib24","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2025.12.001_bib25","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","article-title":"Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion","volume":"3","author":"Wienand","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.001_bib26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1158\/2643-3230.BCD-22-0128","article-title":"Molecular evolution of classic hodgkin lymphoma revealed through whole-genome sequencing of hodgkin and reed sternberg cells","volume":"4","author":"Maura","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"22","key":"10.1016\/j.hoc.2025.12.001_bib27","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"7996","key":"10.1016\/j.hoc.2025.12.001_bib28","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.001_bib29","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(14)00039-8","article-title":"Non-invasive detection of genomic imbalances in Hodgkin\/Reed-sternberg cells in early and advanced stage Hodgkin\u2019s lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study","volume":"2","author":"Vandenberghe","year":"2015","journal-title":"Lancet Haematol"},{"issue":"23","key":"10.1016\/j.hoc.2025.12.001_bib30","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1200\/JCO.20.02573","article-title":"Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-Cell lymphoma","volume":"39","author":"Alig","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.001_bib31","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood.2021012852","article-title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","volume":"139","author":"Meriranta","year":"2022","journal-title":"Blood"},{"issue":"364","key":"10.1016\/j.hoc.2025.12.001_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"14","key":"10.1016\/j.hoc.2025.12.001_bib33","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.001_bib34","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1038\/s41375-024-02375-8","article-title":"Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle cell Lymphoma: results from the EU-MCL network trials","volume":"38","author":"Khouja","year":"2024","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2025.12.001_bib35","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/bloodadvances.2024014136","article-title":"Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels","volume":"9","author":"Moia","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.001_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"issue":"28","key":"10.1016\/j.hoc.2025.12.001_bib37","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating Tumor DNA measurements as early outcome predictors in diffuse large B-Cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.001_bib38","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.22.00826","article-title":"Circulating Tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas","volume":"41","author":"Mutter","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2025.12.001_bib39","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/bloodadvances.2022008174","article-title":"A phase 1\/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL","volume":"7","author":"Cherng","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.001_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-62509-z","article-title":"Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial","volume":"16","author":"Strati","year":"2025","journal-title":"Nat Commun"},{"issue":"34","key":"10.1016\/j.hoc.2025.12.001_bib41","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1200\/JCO-25-01534","article-title":"Remission assessment by circulating tumor DNA in large B-Cell lymphoma","volume":"43","author":"Roschewski","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.12.001_bib42","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood.2024027727","article-title":"Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment","volume":"146","author":"Claudel","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.001_bib43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pathol-050520-044652","article-title":"Molecular monitoring of lymphomas","volume":"18","author":"Schroers-Martin","year":"2023","journal-title":"Annu Rev Pathol"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.001_bib44","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3109\/10428194.2016.1139703","article-title":"Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma","volume":"57","author":"Camus","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.001_bib45","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.hoc.2025.12.001_bib46","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","article-title":"Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring","volume":"26","author":"Zviran","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.001_bib47","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-024-03040-4","article-title":"Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment","volume":"30","author":"Widman","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.001_bib48","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/s41587-021-00900-z","article-title":"Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands","volume":"39","author":"Cohen","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.001_bib49","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.hoc.2025.12.001_bib50","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/nprot.2014.170","article-title":"Detecting ultralow-frequency mutations by Duplex Sequencing","volume":"9","author":"Kennedy","year":"2014","journal-title":"Nat Protoc"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.001_bib51","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"7859","key":"10.1016\/j.hoc.2025.12.001_bib52","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-021-03477-4","article-title":"Somatic mutation landscapes at single-molecule resolution","volume":"593","author":"Abascal","year":"2021","journal-title":"Nature"},{"issue":"8089","key":"10.1016\/j.hoc.2025.12.001_bib53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41586-025-09584-w","article-title":"Somatic mutation and selection at population scale","volume":"647","author":"Lawson","year":"2025","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.001_bib54","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.ccell.2022.10.022","article-title":"Evaluation of cell-free DNA approaches for multi-cancer early detection","volume":"40","author":"Jamshidi","year":"2022","journal-title":"Cancer Cell"},{"issue":"Suppl 13","key":"10.1016\/j.hoc.2025.12.001_bib55","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-2164-16-S13-S1","article-title":"Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation","volume":"16 Suppl 13","author":"Ivanov","year":"2015","journal-title":"BMC Genom"},{"issue":"1\u20132","key":"10.1016\/j.hoc.2025.12.001_bib56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","article-title":"Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin","volume":"164","author":"Snyder","year":"2016","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.001_bib57","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41587-022-01222-4","article-title":"Inferring gene expression from cell-free DNA fragmentation profiles","volume":"40","author":"Esfahani","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.001_bib58","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood-2022-159230","article-title":"Viral cfDNA profiling reveals distinct EBV subtypes and stratifies risk in Hodgkin Lymphomas","volume":"140","author":"Garofalo","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.001_bib59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41375-019-0541-6","article-title":"Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma","volume":"34","author":"Desch","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2025.12.001_bib60","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1182\/bloodadvances.2020003039","article-title":"The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU leuven and LYSA study on cell-free DNA","volume":"5","author":"Buedts","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.001_bib61","first-page":"1171","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin\u2019s lymphoma and facilitates ultrasensitive residual disease detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med (N Y)"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.001_bib62","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study","volume":"106","author":"Camus","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2025.12.001_bib63","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and reed-sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.001_bib64","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2025.12.001_bib65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semcancer.2016.05.001","article-title":"NF-\u03baB deregulation in Hodgkin lymphoma","volume":"39","author":"Weniger","year":"2016","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.001_bib66","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma","volume":"206","author":"Schmitz","year":"2009","journal-title":"J Exp Med"},{"issue":"23","key":"10.1016\/j.hoc.2025.12.001_bib67","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2012-05-428896","article-title":"Analyzing primary Hodgkin and reed-sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma","volume":"120","author":"Tiacci","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.12.001_bib68","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1158\/2767-9764.CRC-23-0140","article-title":"Ultra-deep sequencing reveals the mutational landscape of classical hodgkin lymphoma","volume":"3","author":"Gomez","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"35","key":"10.1016\/j.hoc.2025.12.001_bib69","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin lymphoma","volume":"42","author":"Heger","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.001_bib70","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood.2024027355","article-title":"A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA","volume":"146","author":"Pirosa","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.12.001_bib71","article-title":"Multidimensional characterization of cellular ecosystems in Hodgkin lymphoma","volume":"2025","author":"Aoki","year":"2025","journal-title":"bioRxiv"},{"issue":"18","key":"10.1016\/j.hoc.2025.12.001_bib72","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood-2017-09-808907","article-title":"Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation","volume":"131","author":"Vigan\u00f2","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.001_bib73","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood.2020007683","article-title":"Characterization of DLBCL with a PMBL gene expression signature","volume":"138","author":"Duns","year":"2021","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.hoc.2025.12.001_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70093_43","article-title":"43 | Circulating tumor dna sequencing reveals rapid response kinetics to anti-PD1 based first-line treatment of hodgkin lymphoma: molecular insights from the ghsg nivahl trial","volume":"43","author":"Heger","year":"2025","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.001_bib75","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3324\/haematol.2020.268813","article-title":"Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential","volume":"107","author":"Raman","year":"2022","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.hoc.2025.12.001_bib76","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.001_bib77","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjh.19162","article-title":"Baseline circulating tumour DNA and interim PET predict response in relapsed\/refractory classical Hodgkin lymphoma","volume":"204","author":"Calabretta","year":"2024","journal-title":"Br J Haematol"},{"issue":"S3","key":"10.1016\/j.hoc.2025.12.001_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70093_21","article-title":"21 | Prognostic value of circulating tumor dna in patients with advanced stage classic hodgkin lymphoma treated on SWOG S1826","volume":"43","author":"Paczkowska","year":"2025","journal-title":"Hematol Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882500142X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882500142X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:25:30Z","timestamp":1773955530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985882500142X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S088985882500142X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.12.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating Tumor DNA Assessment in Classic Hodgkin Lymphoma: Ready for Primetime?","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}